EL-ASHWAH, Shaimaa, Jon SALMANTON-GARCIA, Yavuz M BILGIN, Federico ITRI, Pavel ZAK, Barbora WEINBERGEROVÁ, Luisa VERGA, Ali S OMRANI, Maria Gomes da SILVA, Tomas SZOTKOWSKI, Monia MARCHETTI, Caterina BUQUICCHIO, Marcio NUCCI, Martin SCHOENLEIN, Francesca FARINA, Caroline BESSON, Lucia PREZIOSO, Summiya NIZAMUDDIN, Julio DAVILA-VALLS, Sonia MARTIN-PEREZ, Valentina BONUOMO, Van Doesum JAAP, Maria Chiara TISI, Francesco PASSAMONTI, Gustavo-Adolfo MENDEZ, Stef MEERS, Johan MAERTENS, Alberto LOPEZ-GARCIA, Andreas GLENTHOJ, Matteo BONNANI, Ikhwan RINALDI, Irati ORMAZABAL-VELEZ, Jorge LABRADOR, Austin KULASEKARARAJ, Ildefonso ESPIGADO, Fatih DEMIRKAN, De Jonge NICK, Graham P COLLINS, Maria CALBACHO, Ola BLENNOW, Murtadha AL-KHABORI, Tatjana ADZIC-VUKICEVIC, Elena ARELLANO, Bojana MISKOVIC, Milos MLADENOVIC, Anna NORDLANDER, Zdenek RACIL, Emanuele AMMATUNA, Raul CORDOBA, Ditte Stampe HERSBY, Stefanie GRAEFE, Ziad EMARAH, Michaela HANAKOVA, Maria Vittoria SACCHI, Marriyam IJAZ, Laman RAHIMLI, Nunes Rodrigues RAQUEL, Giovanni Paolo Maria ZAMBROTTA, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2024, vol. 65, No 2, p. 199-208. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2023.2280886.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
Authors EL-ASHWAH, Shaimaa, Jon SALMANTON-GARCIA, Yavuz M BILGIN, Federico ITRI, Pavel ZAK, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Luisa VERGA, Ali S OMRANI, Maria Gomes da SILVA, Tomas SZOTKOWSKI, Monia MARCHETTI, Caterina BUQUICCHIO, Marcio NUCCI, Martin SCHOENLEIN, Francesca FARINA, Caroline BESSON, Lucia PREZIOSO, Summiya NIZAMUDDIN, Julio DAVILA-VALLS, Sonia MARTIN-PEREZ, Valentina BONUOMO, Van Doesum JAAP, Maria Chiara TISI, Francesco PASSAMONTI, Gustavo-Adolfo MENDEZ, Stef MEERS, Johan MAERTENS, Alberto LOPEZ-GARCIA, Andreas GLENTHOJ, Matteo BONNANI, Ikhwan RINALDI, Irati ORMAZABAL-VELEZ, Jorge LABRADOR, Austin KULASEKARARAJ, Ildefonso ESPIGADO, Fatih DEMIRKAN, De Jonge NICK, Graham P COLLINS, Maria CALBACHO, Ola BLENNOW, Murtadha AL-KHABORI, Tatjana ADZIC-VUKICEVIC, Elena ARELLANO, Bojana MISKOVIC, Milos MLADENOVIC, Anna NORDLANDER, Zdenek RACIL, Emanuele AMMATUNA, Raul CORDOBA, Ditte Stampe HERSBY, Stefanie GRAEFE, Ziad EMARAH, Michaela HANAKOVA, Maria Vittoria SACCHI, Marriyam IJAZ, Laman RAHIMLI, Nunes Rodrigues RAQUEL, Giovanni Paolo Maria ZAMBROTTA, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO.
Edition LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2024, 1042-8194.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.600 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1080/10428194.2023.2280886
UT WoS 001103157000001
Keywords in English Chronic myeloid leukemia; tirosine kinase inhibitor; COVID-19; SARS-CoV-2; neoplasia; vaccines
Tags 14110212, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 2/2/2024 11:07.
Abstract
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
PrintDisplayed: 29/6/2024 04:20